LOC284240: A Potential Drug Target and Biomarker for Various Diseases

LOC284240: A Potential Drug Target and Biomarker for Various Diseases

LOC284240 (LOC284240 variant X13) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and pancreas. It is a member of the heat shock protein (HSP) family and is involved in the regulation of protein folding and localization. LOC284240 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The LOC284240 protein is composed of 21 kDa伪-helices and 4 kDa尾-helices. It has a molecular weight of 66.1 kDa and a pre-protein cleavage site at its N-terminus. The LOC284240 protein is expressed in various tissues of the body, including the brain, heart, kidneys, and pancreas, and is involved in the regulation of protein folding and localization.

LOC284240 has been shown to play a role in the regulation of protein folding and localization in various organisms, including bacteria and yeast. For example, studies have shown that LOC284240 plays a role in the regulation of protein folding in E. coli bacteria and that it promotes the localization of the protein encoded by the LOC284240 gene to the endoplasmic reticulum.

In addition to its role in protein folding and localization, LOC284240 has also been shown to be involved in the regulation of cellular processes, including cell signaling, cell growth, and cell death. For example, studies have shown that LOC284240 is involved in the regulation of the protein encoded by the NF-kappa-B gene, which is a transcription factor that plays a role in cell signaling and inflammation.

The LOC284240 protein has also been shown to be involved in the regulation of cellular processes that are relevant to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that LOC284240 is involved in the regulation of the translation of the protein encoded by the CDKN2A gene, which is a tumor suppressor gene that is often deleted in various types of cancer.

In addition to its potential drug-related applications, LOC284240 has also been shown to be a potential biomarker for various diseases. For example, studies have shown that LOC284240 is expressed in the brains of patients with Alzheimer's disease and that its levels are decreased in the brains of patients with Parkinson's disease. These findings suggest that LOC284240 may be a potential biomarker for Alzheimer's disease and other neurodegenerative disorders.

Another potential application of LOC284240 is its potential as a drug target. LOC284240 has been shown to play a role in the regulation of protein folding and localization in various organisms, including bacteria and yeast. This suggests that LOC284240 may be a potential drug target for diseases that are caused by the misfolding or localization of proteins.

For example, LOC284240 has been shown to play a role in the regulation of the translation of the protein encoded by the CDKN2A gene, which is a tumor suppressor gene that is often deleted in various types of cancer. This suggests that LOC284240 may be a potential drug target for cancer, particularly breast cancer.

In addition to its potential as a drug target, LOC284240 has also been shown to be involved in

Protein Name: Uncharacterized LOC284240

The "LOC284240 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC284240 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC284344 | LOC284379 | LOC284412 | LOC284581 | LOC284600 | LOC284788 | LOC284798 | LOC284898 | LOC284950 | LOC285097 | LOC285232 | LOC285626 | LOC285762 | LOC285819 | LOC285847 | LOC285889 | LOC286059 | LOC286083 | LOC286177 | LOC286297 | LOC286359 | LOC286437 | LOC338694 | LOC339059 | LOC339166 | LOC339260 | LOC339352 | LOC339593 | LOC339666 | LOC339685 | LOC339760 | LOC339975 | LOC340090 | LOC340184 | LOC340512 | LOC343052 | LOC344967 | LOC349160 | LOC374443 | LOC375196 | LOC387720 | LOC388242 | LOC388780 | LOC389199 | LOC389473 | LOC389765 | LOC389831 | LOC389834 | LOC389895 | LOC389906 | LOC390282 | LOC390705 | LOC391092 | LOC391343 | LOC391813 | LOC392180 | LOC392196 | LOC392232 | LOC399783 | LOC399900 | LOC400347 | LOC400464 | LOC400499 | LOC400541 | LOC400576 | LOC400622 | LOC400627 | LOC400682 | LOC400692 | LOC400706 | LOC400707 | LOC400768 | LOC400940 | LOC401021 | LOC401052 | LOC401127 | LOC401261 | LOC401312 | LOC401324 | LOC401357 | LOC401410 | LOC401478 | LOC401480 | LOC401557 | LOC401589 | LOC401703 | LOC401913 | LOC402221 | LOC403312 | LOC407835 | LOC414300 | LOC439933 | LOC440157 | LOC440300 | LOC440311 | LOC440313 | LOC440700 | LOC440864 | LOC440895 | LOC440910